- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04672824
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Rift Valley Fever Virus (RVFV) Vaccine ChAdOx1 RVF Among Healthy Adult Volunteers in Uganda
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomised, single blind, placebo-controlled, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 RVF vaccine in healthy Ugandan volunteers aged 18-50. The vaccine will be administered intramuscularly.
This study will run concurrently with the first-in-human ChAdOx1 RVF trial in Oxford. Vaccination at the MRC/UVRI and LSHTM Uganda Research Unit, Masaka will only begin upon receiving a favourable opinion of Uganda's trial DSMB of the 7-day post-vaccination safety analysis of the first two lowest dose groups (ChAdOx1 RVF 5 x 10^9vp and ChAdOx1 RVF 2.5 x 10^10vp) of the trial in Oxford.
Volunteers will be recruited and vaccinated at the MRC/UVRI and LSHTM Uganda Research Unit Clinical Research Centre in Masaka. There will be three study groups and a total of 30 volunteers will be enrolled (table 3). Volunteers will be recruited sequentially into Groups 1,2 and 3. Within each group, eligible volunteers will be randomly allocated to receive either ChAdOx1 RVF or placebo of 0.9% Normal Saline in a ratio of 2:1 in group 1 and 5:1 in groups 2 and 3. The DSMB will analyse the 7-day post-vaccination safety data in each group and advise on whether to proceed to the next group with a higher dose .
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Entebbe, Uganda
- MRC/UVRI and LSHTM Uganda Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The volunteer must satisfy all the following criteria to be eligible for the study:
- Male and female healthy adults aged 18 to 50 years
- Able and willing to provide written informed consent
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- For females only, willingness to practice continuous effective contraception during the study.
- Females of childbearing potential must have a negative urine β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and a negative urine β-hCG pregnancy test immediately prior to study vaccine administration
- Agreement to refrain from blood donation during the course of the study
- Healthy in the investigator's clinical judgement basing on the medical history and physical examination performed at screening
- Healthy on the basis of clinical laboratory tests (within the institutional normal laboratory reference ranges) performed at screening.
- Willing to provide verifiable identification to the study team
- Volunteer must have a means to be contacted or be willing to provide locator information to the study team
- Volunteer must pass the Test of Understanding (TOU)
Exclusion Criteria:
The volunteer may not enter the study if any of the following apply:
- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Prior receipt of an investigational vaccine as it may impact on interpretation of the trial data.
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
- Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
- Any history of anaphylaxis in relation to vaccination
- Pregnancy, lactation or willingness/intention to become pregnant during the study
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- History of serious psychiatric condition likely to affect participation in the study
- Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
- Acute illness or temperature ≥37.5°C/99.5°F on the day of vaccination. Volunteer may be rescheduled for enrolment at a later date.
- Major surgery (per the investigator's judgement) within 4 weeks prior to screening or planned major surgery through the course of the study
- Any other serious chronic illness requiring hospital specialist supervision
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 14 units every week
- Suspected or known injecting drug abuse in the 5 years preceding enrolment
- Seropositive for hepatitis B surface antigen (HBsAg)
- Seropositive for hepatitis C virus (antibodies to HCV)
- Any clinically significant abnormal finding on screening biochemistry, haematology and coagulation blood tests or urinalysis
- Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- Prior natural exposure to RVFV as determined by seropositivity for RVFV antigens by ELISA.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ChAdOx1 RVF group 1
Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly
|
Single dose ChAdOx1 vectored vaccine
|
ACTIVE_COMPARATOR: Control group
Placebo (Normal Saline), 0.5ml delivered intramuscularly
|
0.5ml saline placebo
|
EXPERIMENTAL: ChAdOx1 RVF group 2
Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly
|
Single dose ChAdOx1 vectored vaccine
|
EXPERIMENTAL: ChAdOx1 RVF group 3
Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly
|
Single dose ChAdOx1 vectored vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the safety profile of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: AE
Time Frame: The study duration: 3 months from vaccination
|
Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination, occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination, occurrence of unsolicited adverse events for 28 days following the vaccination, and occurrence of serious adverse events during the whole study duration
|
The study duration: 3 months from vaccination
|
Assess the safety profile of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: change in baseline: AE
Time Frame: The study duration: 3 months from vaccination
|
Change from baseline for safety laboratory measures: clinical blood test adverse events (full blood count, liver function tests and renal function) graded on a scaled adapted from the FDA healthy volunteer vaccine scale
|
The study duration: 3 months from vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: GnGc protein antibodies
Time Frame: The study duration: 3 months from vaccination
|
Measures of immunogenicity to the ChAdOx1 RVF vaccine: * ELISA to quantify antibodies to GnGc proteins |
The study duration: 3 months from vaccination
|
Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: RVFV neutralising antibodies
Time Frame: The study duration: 3 months from vaccination
|
Measures of immunogenicity to the ChAdOx1 RVF vaccine: * RVFV neutralising antibody titres |
The study duration: 3 months from vaccination
|
Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: ELISpot & flow cytometry
Time Frame: The study duration: 3 months from vaccination
|
Measures of immunogenicity to the ChAdOx1 RVF vaccine: * Ex vivo ELISpot and flow cytometry responses to GnGc |
The study duration: 3 months from vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Arbovirus Infections
- Vector Borne Diseases
- Bacterial Infections and Mycoses
- Parasitic Diseases
- Protozoan Infections
- Mycoses
- Body Temperature Changes
- Hemorrhagic Fevers, Viral
- Hepatitis
- Bunyaviridae Infections
- Hepatitis, Viral, Animal
- Hepatitis, Animal
- Fever
- Coccidioidomycosis
- Coccidiosis
- Rift Valley Fever
Other Study ID Numbers
- RVF002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rift Valley Fever
-
University of OxfordCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
U.S. Army Medical Research and Development CommandCompletedRift Valley FeverUnited States
-
U.S. Army Medical Research and Development CommandCompleted
-
U.S. Army Medical Research and Development CommandRecruitingRift Valley FeverUnited States
-
U.S. Army Medical Research and Development CommandCompletedRift Valley FeverUnited States
-
Washington State UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Washington University... and other collaboratorsRecruitingHemorrhagic Fevers, Viral | Rift Valley FeverCongo, The Democratic Republic of the, Kenya, Tanzania, Uganda
-
University of ArizonaTerminatedCoccidioidomycosis | Valley FeverUnited States
-
George R ThompsonMayne Pharma International Pty LtdWithdrawnCoccidioidomycosis | Valley FeverUnited States
-
Meir Medical CenterCompleted
Clinical Trials on ChAdOx1 RVF
-
University of OxfordCompleted
-
U.S. Army Medical Research and Development CommandRecruitingRift Valley FeverUnited States
-
U.S. Army Medical Research and Development CommandCompletedRift Valley FeverUnited States
-
François SpertiniUniversity of OxfordCompletedTuberculosis | Mycobacterium Tuberculosis, Protection AgainstSwitzerland
-
U.S. Army Medical Research and Development CommandCompleted
-
U.S. Army Medical Research and Development CommandCompletedRift Valley FeverUnited States
-
Vaccitech (UK) LimitedRecruiting
-
University of OxfordCompleted
-
Vaccitech (UK) LimitedCompleted
-
University of OxfordTerminatedMERS (Middle East Respiratory Syndrome)United Kingdom